Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents
Daihiko Hakuno, … , Satoshi Ogawa, Keiichi Fukuda
Daihiko Hakuno, … , Satoshi Ogawa, Keiichi Fukuda
Published June 14, 2010
Citation Information: J Clin Invest. 2010;120(7):2292-2306. https://doi.org/10.1172/JCI40973.
View: Text | PDF | Corrigendum
Research Article

Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents

  • Text
  • PDF
Abstract

Valvular heart disease (VHD) is the term given to any disease process involving one or more of the heart valves. The condition can be congenital or acquired, for example as a result of atherosclerosis or rheumatic fever. Despite its clinical importance, the molecular mechanisms underlying VHD remain unknown. We investigated the pathophysiologic role and molecular mechanism of periostin, a protein that plays critical roles in cardiac valve development, in degenerative VHD. Unexpectedly, we found that periostin levels were drastically increased in infiltrated inflammatory cells and myofibroblasts in areas of angiogenesis in human atherosclerotic and rheumatic VHD, whereas periostin was localized to the subendothelial layer in normal valves. The expression patterns of periostin and chondromodulin I, an angioinhibitory factor that maintains cardiac valvular function, were mutually exclusive. In WT mice, a high-fat diet markedly increased aortic valve thickening, annular fibrosis, and MMP-2 and MMP-13 expression levels, concomitant with increased periostin expression; these changes were attenuated in periostin-knockout mice. In vitro and ex vivo studies revealed that periostin promoted tube formation and mobilization of ECs. Furthermore, periostin prominently increased MMP secretion from cultured valvular interstitial cells, ECs, and macrophages in a cell type–specific manner. These findings indicate that, in contrast to chondromodulin I, periostin plays an essential role in the progression of cardiac valve complex degeneration by inducing angiogenesis and MMP production.

Authors

Daihiko Hakuno, Naritaka Kimura, Masatoyo Yoshioka, Makio Mukai, Tokuhiro Kimura, Yasunori Okada, Ryohei Yozu, Chisa Shukunami, Yuji Hiraki, Akira Kudo, Satoshi Ogawa, Keiichi Fukuda

×

Figure 8

Periostin induces the secretion of MMPs from VICs, ECs, and macrophages in vitro.

Options: View larger image (or click on image) Download as PowerPoint
Conceptual framework for the roles of periostin and chondromodulin I in ...
(A) Light microscopy, immunofluorescence staining, and Western blot analysis of cultured rat VICs. The VICs were fibroblast-like in appearance and expressed chondromodulin I, but did not express acetylated LDL. The ECs in the inset and the rat eye in the Western blot served as positive controls. Scale bars: 100 μm. (B) Expression and secretion of collagen I, α-SMA, MMP-2, and MMP-13 by VICs following periostin stimulation. Conditioned media and cell lysates were obtained from VICs with or without periostin stimulation and subjected to Western blot analysis. Periostin prominently stimulated secretion of MMP-2 and MMP-13 by VICs, whereas collagen I production and α-SMA expression were unchanged. Densitometric quantitative analysis of MMP levels in the conditioned media from the VIC cultures is also shown. (C) RT-PCR analysis of MMP expression in VICs after periostin stimulation. Periostin increased the transcription of Mmp13, but not that of Mmp2 or Mmp9. Cartilage served as a positive control. Also shown is Mmp2 mRNA expression in VICs after stimulation with or without periostin for 5 days. (D and E) Expression and secretion of MMPs by human coronary artery ECs (D) and cultured mouse BM-derived macrophages (E) following periostin stimulation. Densitometric quantitative analyses of MMP levels in the conditioned media from cultures of ECs and macrophages is also shown. Periostin significantly induced secretion of MMP-2 and MMP-9 from ECs and macrophages, respectively. *P < 0.05.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts